Leukemia Journal

Overview

publication venue for

• Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study 2019
• Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications 2019
• Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia 2019
• Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia 2019
• Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia 2019
• Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance 2019
• A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.  32:547-549. 2018
• Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.  32:353-363. 2018
• High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.  32:419-428. 2018
• Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma 2018
• Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.  32:83-91. 2018
• Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 2018
• CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.  31:2254-2257. 2017
• Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.  31:1882-1893. 2017
• Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.  31:1368-1374. 2017
• Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.  31:1391-1397. 2017
• Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide 2017
• Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients.  31:970-973. 2017
• Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.  31:585-592. 2017
• Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.  31:625-636. 2017
• A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.  31:393-402. 2017
• Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen 2017
• A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.  31:2726-2731. 2017
• A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.  31:241-244. 2017
• Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.  31:115-122. 2017
• Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.  31:136-142. 2017
• Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.  31:151-158. 2017
• The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.  30:2402-2405. 2016
• Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.  30:1116-25. 2016
• Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.  30:1133-42. 2016
• Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.  30:649-57. 2016
• EBV-miR-BHRF1-2 targets PRDM1/Blimp1: Potential role in EBV lymphomagenesis.  30:594-604. 2016
• Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.  30:190-9. 2016
• FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice.  30:1-13. 2016
• In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche 2015
• Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.  29:2238-47. 2015
• BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.  29:1832-8. 2015
• Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.  29:1267-78. 2015
• Immunosuppressive therapy of LGL leukemia: Prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).  29:886-94. 2015
• A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.  29:1390-401. 2015
• Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.  29:137-44. 2015
• Functional characterization of BTK C481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors.  29:895-900. 2015
• Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.  29:895-900. 2015
• IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.  29:415-22. 2015
• IL10 receptor is a novel therapeutic target in DLBCLs.  29:1684-94. 2015
• Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.  29:1290-300. 2015
• Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.  29:1981-92. 2015
• SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.  29:847-57. 2015
• Risk of myeloid neoplasms after solid organ transplantation.  28:2317-23. 2014
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.  28:649-57. 2014
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.  28:649. 2014
• Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.  28:1698-704. 2014
• Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: Implications for epigenetic therapy.  28:147-54. 2014
• High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): Cytogenetic features, clinical characteristics and outcome.  28:1511-8. 2014
• Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031.  28:1467-71. 2014
• Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.  28:174-8. 2014
• Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12 482 persons from the national health and nutritional examination survey.  28:1537-42. 2014
• Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.  27:2341-50. 2013
• Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.  27:2177-86. 2013
• AKT is a therapeutic target in myeloproliferative neoplasms.  27:1882-90. 2013
• Toll-like receptor alterations in myelodysplastic syndrome.  27:1832-40. 2013
• Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety.  27:1707-14. 2013
• Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis.  27:1310-5. 2013
• Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.  27:823-8. 2013
• Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.  27:852-60. 2013
• MiR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.  27:344-52. 2013
• A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.  27:220-5. 2013
• Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.  27:66-74. 2013
• Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.  27:208-12. 2013
• Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study.  26:2103-13. 2012
• Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.  26:1771-8. 2012
• Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: Ontogenetic implications.  26:1638-46. 2012
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.  26:893-901. 2012
• The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.  26:481-9. 2012
• NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.  25:281-9. 2011
• Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.  25:145-52. 2011
• PHF6 mutations in adult acute myeloid leukemia.  25:130-4. 2011
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.  24:1302-9. 2010
• A multi-center phase i study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.  23:2259-64. 2009
• Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.  23:1605-13. 2009
• Monoclonal antibodies against IREM-1: Potential for targeted therapy of AML.  23:1587-97. 2009
• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.  23:2147-52. 2009
• Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates.  23:900-4. 2009
• TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.  23:905-11. 2009
• Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.  23:1139-51. 2009
• Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.  23:574-80. 2009
• Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.  23:287-91. 2009
• Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.  22:2176-83. 2008
• On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.  22:1707-11. 2008
• The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.  22:1917-24. 2008
• Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib.  22:1755-66. 2008
• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.  22:1200-6. 2008
• Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.  22:1139-43. 2008
• TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.  21:1658-68. 2007
• Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements.  21:1481-7. 2007
• The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.  21:739-46. 2007
• Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.  21:489-93. 2007
• Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.  21:169-74. 2007
• Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.  20:2025-33. 2006
• Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2.  20:1790-9. 2006
• Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.  20:979-86. 2006
• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.  20:952-7. 2006
• Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.  20:212-7. 2006
• Results of a phase I/II trial adding carmustine (300mg/m²) to melphalan (200mg/m²) in multiple myeloma patients undergoing autologous stem cell transplantation.  20:345-9. 2006
• Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide [3].  19:873-5. 2005
• Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.  19:39-43. 2005
• KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).  19:27-30. 2005
• Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998).  18:1605-10. 2004
• Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.  18:1352-6. 2004
• Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: A report from the Children's Cancer Group.  18:939-47. 2004
• Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study.  18:309-15. 2004
• Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: Possible mediation of hypoxia-inducible factor-1α.  17:2065-73. 2003
• A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.  17:1967-72. 2003
• Low expression of the myeloid differentiation antigens CD65s, a feature of poorly differentiated AML in older adults: Study of 711 patients enrolled in ECOG trials.  17:1544-50. 2003
• Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.  17:481-7. 2003
• Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.  17:604-11. 2003
• Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.  17:314-8. 2003
• Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.  16:1673-9. 2002
• Long-term follow-up of short intensive chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin lymphoma: A children's cancer group report.  16:594-600. 2002
• Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).  16:1627-36. 2002
• Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): No evidence for intrinsic growth advantage of PNH clones.  16:2243-8. 2002
• Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.  16:1484-9. 2002
• Radioimmunotherapy for model B cell malignancies using ⁹⁰Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.  16:60-6. 2002
• Radioimmunotherapy for model B cell malignancies using ⁹⁰Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.  16:60-6. 2002
• Retinoic acid syndrome: A problem of the past?.  16:160-1. 2002
• Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.  15:963-70. 2001
• Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission.  15:757-63. 2001
• The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stems cells.  14:1777-84. 2000
• A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes.  14:1614-20. 2000
• Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.  14:1577-82. 2000
• Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia.  14:1345-8. 2000
• Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4.  14:292-8. 2000
• Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21.  13:1534-8. 1999
• Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid.  13:1258-65. 1999
• Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis.  13:1243-53. 1999
• A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.  12:865-8. 1998
• Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.  11:1533-9. 1997
• Rapid induction of B-cell lymphomas by avian leukosis virus.  11:179-82. 1997
• Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia.  11:886-9. 1997
• Studies of decitabine with allogeneic progenitor cell transplantation.  11:S32-4. 1997
• c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells.  10:1436-42. 1996
• Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.  10:1237-40. 1996
• Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.  10:321-6. 1996
• c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.  10:229-37. 1996
• Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.  10:32-9. 1996
• A pilot study of the biologic and therapeutic effects of granulocyte colonystimulating factor (filgrastim) in patients with acute myelogenous leukemia.  9:1799-804. 1995
• Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.  9:1631-7. 1995
• Familial acute myeloid leukemia and DiGuglielmo syndrome.  9:1091-4. 1995
• Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: Long-term follow-up results of study by Cancer and Leukemia Group B.  9:1116-20. 1995
• Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.  9:244-8. 1995
• Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia.  9:1653-60. 1995
• Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience.  8:S33-7. 1994
• Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.  8:1290-3. 1994
• Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines.  8:1191-6. 1994
• Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience.  8:929-33. 1994
• Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.  8:749-57. 1994
• Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.  8:758-67. 1994
• A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.  8:688-93. 1994
• Phase I-II trial of high dose ARA-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.  8:531-4. 1994
• In vitro establishment of AIDS-related lymphoma cell lines: Phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection.  7:1621-9. 1993
• Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL.  7:1020-5. 1993
• Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.  7:832-7. 1993
• Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.  7:758-9. 1993
• Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.  7:1000-4. 1993
• Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.  6:1189-91. 1992
• Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.  6:1185-8. 1992
• Diffuse large cell lymphoma. Prognostic factors with treatment.  5:32-7. 1991
• Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase) - a pilot study.  5:991-8. 1991
• Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.  5:386-91. 1991
• Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia.  5:540-7. 1991
• Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.  5:712-4. 1991
• Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.  4:625-30. 1990
• Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).  4:177-83. 1990
• Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.  3:446-52. 1989
• Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: Results of the L-16M protocol.  3:115-21. 1989
• Establishment and characterization of two human myeloma cell lines secreting kappa light chains.  3:729-35. 1989
• Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia.  3:440-5. 1989
• Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.  3:339-48. 1989
• Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies.  2:19-26. 1988
• The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.  2:642-7. 1988
• Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2.  1:305-7. 1987
• Juvenile chronic myeloid leukemia: Therapeutic insights.  1:730-3. 1987
• Clonal chromosomal abnormalities in CD34+/CD-38 hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.  24:1525-8. 2010
• High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis [16].  20:2067-2070. 2006
• BRAF gene is not mutated in plasma cell leukemia and multiple myeloma [4].  17:2238-40. 2003
• Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571 [3].  15:1795-7. 2001
• Allogeneic and autologous transplantation for chronic lymphocytic leukemia.  15:1317-25. 2001
• Extensive bone marrow necrosis associated with multiple myeloma [3].  13:2118-20. 1999
• Discordant erythropoiesis in CML (multiple letters) [3].  12:444-5. 1998
• Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) [1].  11:170. 1997
• International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) 2009
• Chronic myeloid leukemia - Some topical issues.  21:1347-52. 2007
• Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma 2019
• Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial 2017
• A unique aptamer-drug conjugate for targeted therapy of multiple myeloma 2016
• Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia 2016
• Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia 2015
• Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia 2015
• Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis 2015
• The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma 2015
• Bone marrow angiogenesis in myeloma and its precursor disease: A prospective clinical trial 2014
• Acceleration of Bcr-Abl + leukemia induced by deletion of JAK2 2014
• Improved long-term survival in multiple myeloma up to the age of 80 years 2014
• Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: Results from children's oncology group study AALL0031 2014
• Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies 2014
• Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: Incidence and prognostic significance 2013
• Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma 2012
• Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms 2011
• DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms 2011
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration 2010
• Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines 2010
• Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia 2009
• Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis 2009
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML 2009
• Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma 2009
• BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells 2008
• Systematic genomic screen for tyrosine kinase mutations in CLL 2008
• A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease 2008
• An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia 2008
• Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation 2008
• Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients 2008
• JAK2 Mutations are present in all cases of polycythemia vera 2008
• The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma 2008
• Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment [6] 2008
• A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias [10] 2007
• JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? [15] 2006
• A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies [4] 2006
• NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis [4] 2006
• Ph-positive and -negative myeloproliferative syndromes may co-exist [1] 2004
• Thalidomide therapy induces response in relapsed mantle cell lymphoma [7] 2003
• Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera [1] 2003
• Clinical activity of arsenic trioxide in Burkitt-like lymphoma [3] 2003
• Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells 2016
• Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both 2016
• Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 2015
• Clonal evolution in hematological malignancies and therapeutic implications 2014
• Inherited genetic susceptibility to multiple myeloma 2014
• MYD88 and beyond: Novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia 2014
• New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG) 2014
• Update on second primary malignancies in multiple myeloma: A focused review 2014
• Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group 2013
• The ASXL-BAP1 axis: New factors in myelopoiesis, cancer and epigenetics 2013
• Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis 2012
• Management of treatment-emergent peripheral neuropathy in multiple myeloma 2012
• Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma 2011
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management 2010
• Monoclonal B-cell lymphocytosis (MBL): Biology, natural history and clinical management 2010
• International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review 2009
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma 2009
• Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: Support for genetic factors in pathogenesis 2009
• International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation 2009
• JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science 2008
• Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria 2008
• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma 2008
• Predicting the effect of transcription therapy in hematologic malignancies 2005
• Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies 2003
• Elitek™-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 2003
• Sphingosine 1-phosphate as a therapeutic agent 2002
• Therapy of acute promyelocytic leukemia: All-trans retinoic acid and beyond 1998
• New understanding of the pathogenesis of CML: A prototype of early neoplasia 1997
• Differentiating therapy in acute myeloid leukemia 1996
• Differentiating therapy in acute myeloid leukemia 1996
• Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia 1996
• Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment 1993
• Basophilic differentiation in acute promyelocytic leukemia 1993
• Pediatric leukemia/lymphoma with t(8;14)(q24;q11) 1992
• Acute lymphoblastic leukemia: Present and future 1992
• Blastic phase of chronic myeloid leukemia (blCML): A proposal for standardization of diagnostic and response criteria 1990
• High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease 1989
• Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? 2005
• Spotlight on acute promyelocytic leukemia: Controversies and challenges 2002
• A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis 2019
• Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma 2019
• The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab 2019

Identity

Linking ISSN

• 0887-6924

International Standard Serial Number (ISSN)

• 0887-6924

Electronic International Standard Serial Number (EISSN)

• 1476-5551